Furthermore, several studies showcase the potential for baseline monocyte subsets to predict treatment responses in RA to anti-TNF therapy and methotrexate (MTX) [28,29], where frequencies of classical and intermediate monocytes increase in non-responders compared to responders [28]. This evidence concerns the gene TNF and rheumatoid arthritis.